based on the annual financial statements for 2024. To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.

Company's share capital will be NOK 38,702,333.04. The total number of shares in the Company will be 92,148,412 shares, each with a nominal value of NOK 0.42.

• Production cost at sea 44,0 NOK per kg WFE • 3 929 tons WFE harvested, up 42% from 2 765 tons WFE in Q1-24 ...

The price per Offer Share (the "Subscription Price") will be NOK 1.00 per share. The final number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of ...

231,156,736 shares, each with a par value of NOK 1.00. All the exercised options have been granted in accordance with the Company's To subscribe to Press releases from this issuer, visit the ...

to provide outstanding solutions for healthcare professionals globally. The Company is headquartered in Oslo, Norway. Further information is available at www.observemedical.com. This information is ...

a full year ahead of plan. The company also reported a 50% year-over-year improvement in its adjusted EBIT margin for the quarter, which rose to 14.1%, ...

issue amount of USD 200,000,000 and ISIN NO0013063495 on Euronext Oslo Børs. To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or ...

representing 85% of Convatec's 2021 market for the product. · Global Reach: Orders received from 27 countries, with 16 countries placing multiple/repeat orders. For the whole UnoMeter portfolio, the ...

currently employ close to 500 people across both offshore and onshore locations. The company operates a wide range of work and survey ROVs from its fleet of To subscribe to Press releases from this ...

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, ...

will be subject to lock-up of 180 days. Further, the shares held by the Company's CEO and Deputy CEO will be subject to a lock-up of 720 days, following which 1/3 of the shares will be released from ...